Class 2 Medicines Recall: Curaleaf Oil

MHRA Drug & Device Alerts

Published March 12th, 2026

Detected March 13th, 2026

Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 Medicines Recall for three batches of Curaleaf Oil due to low THC content. Healthcare professionals are instructed to stop supplying the affected batches immediately.

View original document View source feed page

What changed

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Class 2 Medicines Recall for three specific batches of Curaleaf Oil [FS] 10mg/ml THC, 10mg/ml CBD (30ml) manufactured by Rokshaw Limited Trading as Curaleaf Laboratories. The recall is due to a stability study failure indicating THC content below acceptable levels. The affected batch numbers are B11/01/24-30, B11/04/24-30, and B11/05/24-30.

Healthcare professionals are required to immediately stop supplying these batches, quarantine all affected stock, and return it to their supplier. Patients are advised that no action is required from them, and they should continue using the product as prescribed. This recall is at the wholesaler and pharmacy level. No adverse events have been reported for these batches.

What to do next

Stop supplying affected batches of Curaleaf Oil immediately.
Quarantine all affected stock.
Return quarantined stock to your supplier according to their approved process.

Source document (simplified)

Class 2 Medicines Recall: Rokshaw Limited Trading as Curaleaf Laboratories, Curaleaf Oil [FS] 10mg/ml THC, 10mg/ml CBD (30ml), EL(26)A/13

Curaleaf Laboratories are recalling three batches of Curaleaf Oil [FS] 10mg/ml THC 10mg/ml CBD (30ml) due to low THC content.

From: Medicines and Healthcare products Regulatory Agency Published 12 March 2026 Message type: Medicines recall/notification Medical specialty: Dispensing GP practices and Pharmacy Issued: 12 March 2026

DMRC reference number

DMRC- 38668711

Marketing Authorisation Holder

Rokshaw Limited Trading as Curaleaf Laboratories

Medicine Details

Curaleaf Oil [FS] 10mg/ml THC, 10mg/ml CBD (30ml)

MS 41467

Active ingredient: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)

SNOMED code: N/A

GTIN: N/A

Affected Lot Batch Numbers

| Batch No. | Expiry Date | Pack Size | First Distributed |
| --- | --- | --- | --- |
| B11/01/24-30 | 28/02/2026 | 30 mL | 12/08/2024 |
| B11/04/24-30 | 31/07/2026 | 30 mL | 03/12/2024 |
| B11/05/24-30 | 31/07/2026 | 30 mL | 04/02/2025 |

Background

Curaleaf Laboratories have informed MHRA of a confirmed stability study failure where the THC content is below the acceptable level in Curaleaf Oil [FS] 10mg/ml THC 10mg/ml CBD (30ml).

The above batches of Curaleaf Oil [FS] 10mg/ml THC 10mg/ml CBD (30ml) are being recalled out of an abundance of caution.

Advice for Healthcare Professionals:

Stop supplying the above batches immediately. Quarantine all stock and return it to your supplier using your supplier’s approved process.

Advice for Healthcare Professionals to Provide to Patients:

No action is required by patients, the recall is at the wholesaler and pharmacy level.

Patients should continue to use the product as instructed by their healthcare professional. No adverse events have been received for these batches of products. If patients have any questions about this medication, you should speak to their healthcare professional in the first instance.

Patients who experience adverse reactions or have any questions about the medication should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Additional information:

For all medical information enquiries and information on this product, please email orders@curaleaflaboratories.co.uk, or telephone +44 0191 7431007.

For stock control enquiries please email orders@curaleaflaboratories.co.uk, or telephone +44 0191 7431007.

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

Defective Medicines Report Centre

10 South Colonnade

Canary Wharf

London

E14 4PU

Telephone +44 (0)20 3080 6574

DMRC@mhra.gov.uk